Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer
Authors
Keywords
Taxanes, Neuropathy, Metastatic breast cancer, <em class=EmphasisTypeItalic >nab</em>-Paclitaxel, Docetaxel, Paclitaxel
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 75, Issue 4, Pages 659-670
Publisher
Springer Nature
Online
2015-01-17
DOI
10.1007/s00280-014-2607-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Anti-Diabetic Drug Metformin Protects against Chemotherapy-Induced Peripheral Neuropathy in a Mouse Model
- (2014) Qi-Liang Mao-Ying et al. PLoS One
- Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: a pilot randomized clinical trial
- (2014) Samuel Oliveira de Afonseca et al. Sao Paulo Medical Journal
- CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel
- (2013) D. L. Hertz et al. ANNALS OF ONCOLOGY
- Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
- (2013) Ellen M. Lavoie Smith et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Neuropathy-Inducing Effects of Eribulin Mesylate Versus Paclitaxel in Mice with Preexisting Neuropathy
- (2013) Krystyna M. Wozniak et al. NEUROTOXICITY RESEARCH
- Impact of Chemotherapy-Induced Peripheral Neuropathy on Treatment Delivery in Nonmetastatic Breast Cancer
- (2013) Rebecca M. Speck et al. Journal of Oncology Practice
- GWAS-based association betweenRWDD3andTECTAvariants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients
- (2012) Troels K. Bergmann et al. ACTA ONCOLOGICA
- Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: A randomized double-blind placebo controlled trial
- (2012) Zohreh Ghoreishi et al. BMC CANCER
- Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival
- (2012) William J. Gradishar et al. Clinical Breast Cancer
- A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101
- (2012) R. M. Baldwin et al. CLINICAL CANCER RESEARCH
- Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
- (2012) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer
- (2012) Bryan P. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation
- (2012) Karima Osmani et al. JOURNAL OF NEUROLOGY
- Development and Psychometric Evaluation of the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool
- (2011) Cindy S. Tofthagen et al. CANCER NURSING
- Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice
- (2011) K. M. Wozniak et al. CANCER RESEARCH
- Chemotherapy-Induced Peripheral Neuropathy: Prevention and Treatment
- (2011) D R Pachman et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Prevalence and Characteristics of Painful Diabetic Neuropathy in a Large Community-Based Diabetic Population in the U.K.
- (2011) C. A. Abbott et al. DIABETES CARE
- Weekly docetaxel in metastatic breast cancer patients: No superior benefits compared to three-weekly docetaxel
- (2011) Carolien P. Schröder et al. EUROPEAN JOURNAL OF CANCER
- Scrambler Therapy May Relieve Chronic Neuropathic Pain More Effectively Than Guideline-Based Drug Management: Results of a Pilot, Randomized, Controlled Trial
- (2011) Giuseppe Marineo et al. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
- Case report of a patient with chemotherapy-induced peripheral neuropathy treated with manual therapy (massage)
- (2011) Joan Elizabeth Cunningham et al. SUPPORTIVE CARE IN CANCER
- Evaluation of acupuncture in the management of chemotherapy-induced peripheral neuropathy
- (2011) G. K. Donald et al. Acupuncture in Medicine
- Acupuncture for chemotherapy-induced peripheral neuropathy (CIPN): a pilot study using neurography
- (2011) Sven Schroeder et al. Acupuncture in Medicine
- Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy
- (2010) Dawn L. Hershman et al. BREAST CANCER RESEARCH AND TREATMENT
- Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer
- (2010) Javier Cortes et al. EJC SUPPLEMENTS
- Chemotherapy-Induced Peripheral Neurotoxicity assessment: A critical revision of the currently available tools
- (2010) Guido Cavaletti et al. EUROPEAN JOURNAL OF CANCER
- Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184
- (2010) David Cella et al. GYNECOLOGIC ONCOLOGY
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients WithHER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens
- (2010) Vicente Valero et al. JOURNAL OF CLINICAL ONCOLOGY
- Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7
- (2010) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study
- (2010) Michael Andersson et al. JOURNAL OF CLINICAL ONCOLOGY
- Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties
- (2010) Kathleen A. Griffith et al. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
- The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial
- (2010) Lisa A. Kottschade et al. SUPPORTIVE CARE IN CANCER
- A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA
- (2010) Debra L. Barton et al. SUPPORTIVE CARE IN CANCER
- Relationship between GSTP1 Ile105Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity
- (2009) O. Mir et al. ANNALS OF ONCOLOGY
- Significantly Longer Progression-Free Survival Withnab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
- (2009) William J. Gradishar et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-Induced Peripheral Neuropathy as a Predictor of Neuropathic Pain in Breast Cancer Patients Previously Treated With Paclitaxel
- (2009) Cielito C. Reyes-Gibby et al. JOURNAL OF PAIN
- Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02
- (2009) Kojiro Shimozuma et al. SUPPORTIVE CARE IN CANCER
- A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer
- (2008) G. Fountzilas et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer
- (2008) Edgardo Rivera et al. CANCER
- Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy
- (2008) Ravi D. Rao et al. CANCER
- Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activity
- (2008) Noelle Callizot et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Peripheral nerve damage associated with administration of taxanes in patients with cancer
- (2008) Andreas A. Argyriou et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A Questionnaire Survey of Physicians' Perspectives Regarding the Assessment of Chemotherapy-induced Peripheral Neuropathy in Patients with Breast Cancer
- (2008) K. Kuroi et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment
- (2008) Kathy S. Albain et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
- (2008) Andrew D. Seidman et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study)
- (2008) Katsumasa Kuroi et al. SUPPORTIVE CARE IN CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now